IL6R and COVID-19: Along with plant-produced mAbs against the S protein [35,61], plant-produced anti-IL-6R mAb and mAbs against that of other cytokines may provide a less-expensive, yet equally potent treatment option for COVID-19 and other inflammatory diseases.